This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Toronto Ottawa Heart Summit 



Celebrating our 21st Anniversary

Date: June 9-10, 2018
Visit the Conference website
We are excited to announce that the Summit will be co-located with the 2018 International Symposium on Atherosclerosis (ISA) 


This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the University of Ottawa’s Office of Continuing Professional Development. You may claim a maximum of 13.0 hours.

This Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the University of Ottawa’s Office of Continuing Professional Development for up to 13.0 Mainpro+ credits.


La présente activité est une activité d'apprentissage collectif agréée (section 1), au sens que lui donne le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada; elle a été approuvée par le Bureau de formation professionnelle continue de l’Université d’Ottawa. Vous pouvez déclarer un maximum de 13,0 heures.

Ce programme d’apprentissage en groupe répond aux critères de certification du Collège des médecins de famille du Canada et le Bureau de formation professionnelle continue de l’Université d’Ottawa lui accorde jusqu’à 13,0 crédits Mainpro+.


program directors

Peter Liu, MD
Chief Scientific Officer
University of Ottawa Heart Institute

Michael Farkouh, MD
Peter Munk Chair in Multinational Trials
Director, Heart and Stroke Richard Lewar Centre of Excellence


Program agenda

Day 1 SATURDAY, JUNE 9, 2018
Toronto Ottawa Heart Summit

7:00 Registration and Breakfast
7:50 Official Welcome and Introduction
Drs. Peter Liu and Michael Farkouh
8:00 PLENARY LECTURE: Prevention of CV Disease in 2018: An Epidemiologist's Perspective
Dr. Kausik Ray
TOHS Session 1: Artificial Intelligence Chair:
Dr. Peter Liu
8:30 The Algorithm for Precision Medicine using Artificial Intelligence
Dr. Henry Lieberman
8:55 Artificial Intelligence in Health Care
Dr. Garth Gibson
9:20 Transdermal Optical Imaging and Its Potential Applications in Cardiovascular Health Monitoring
Dr. Kang Lee
9:45 Active Learning: Case-based panel discussion
10:05 Health Break
TOHS Session 2: At Risk Populations for Cardiovascular Disease Chair:
Dr. Sheldon Tobe
10:30 Indigenous
Dr. Sheldon Tobe
10:50 South Asians
Dr. Milan Gupta
11:10 Immigrant Data
Dr. Jack Tu
11:30 Prevention of Coronary Artery disease and the ECAD Trail
Dr. Michael Domanski 
11:50 Active Learning: Case-based panel discussion
12:05 LUNCH
1:05 PLENARY LECTURE: History of Cardiology since 1900
Dr. Eugene Braunwald
TOHS Session 3: Heart Failure Chair:
Dr. Douglas Lee
1:35 HFpEF: Mechanism and Management
Dr. Marcus Flather
2:00 Restoring the Hearty Failure Patient to Their Optimal Physiological State
Dr. Peter Liu
2:25 Innovative Technologies: CardioMems & Leadless Pacemaker
Dr. Calum Redpath
2:50 Active learning: Case-based panel discussion
3:10 Health Break TOHS Session 4: Antithrombotic Guideline Updates/Atrial Fibrillation Chair:
Dr. Paul Dorian
3:30 Anticoagulants/AF Guideline Update: Silent AF: How to Manage?
Dr. Paul Dorian
3:50 Antiplatelet Guideline Update: DAPT: When and for How Long?
Dr. Shamir Mehta
4:10 COMPASS Trial
Dr. Shaun Goodman
Dr. Nassir Marrouche
4:50 Active Learning: Case-based panel discussion
5:10 Adjournment


Day 2 SUNDAY JUNE 10, 2018
International Symposium on Atherosclerosis/Toronto Ottawa Heart Summit

7:30 Registration
8:20 Welcome and Introduction
Drs. Peter Liu and Michael Farkouh
ISA Plenary Session 1-1: Atherosclerosis: The Global View
Chairs: Drs. Eugene Braunwald and Peter Liu
8:25-10:30 TOHS registrants may attend this session
For details, go to:
Population Approaches to Reducing CVD Globally
Dr. Salim Yusuf
Leukocytes and Clonal Hematopoiesis as Causal Contributors to Atherothrombosis
Dr. Peter Libby
Dr. Paul Ridker
The Evolving Science of Health: Imaging, Genetics and Behavior
Dr. Valentin Fuster
10:30 Health Break
ISA/TOHS CS 1-2: Cardiovascular Disease Risk Factor Interventions
Chairs: Drs. Peter Liu and John French
11:00 Can We Postpone the Development of Atherosclerotic Disease until Age 100?
Dr. Eugene Braunwald
11:20 Is Obesity a Causative Risk Factor for CAD? Insights from Genetic and Clinical Studies
Drs. Robert Dent and Ruth McPherson
11:50 New Standards in HTN Treatment
Dr. Sheldon Tobe
12:15 Further CV Outcomes with PCSK9 Inhibition
Dr. Jacques Genest
12:40 Active Learning: Case-based panel discussion
1:00 LUNCH
ISA/TOHS CS 1-9: Diabetes
Chair: Dr. Michael Farkouh
2:30 Kidney Disease in Patients with Diabetes
Dr. Philip McFarlane
2:50 Cardiovascular Complications of Diabetes Mellitus
Dr. Gregory Barsness
3:10 What Cardiologists Need to Know of New Diabetes Treatment?
Dr. Ruth McPherson
3:30 SGLT2 and Heart Failure: What Are the Mechanisms?
Dr. Subodh Verma
3:50 Active Learning Q & A with Panel
4:10 Adjournment



At the end of this symposium, participants should be able to:

  • recognize moving targets in risk factor management and implement preventative cardiology recommendations and advocate health promotion
  • identify how machine learning and artificial intelligence can augment physician’s diagnostic skills and help tailor treatment to individual patient and disease
  • explain relevant screening and/or management strategies appropriate for CV risk stratification and prevention in at-risk populations
  • discuss new and emerging theories and management in heart failure, and differentiate between reduced and preserved ejection fraction patients
  • review appropriate management of anticoagulant and antiplatelet therapies across various cardiovascular conditions
  • summarize pharmacological and non-pharmacological options in atrial fibrillation management
  • consider emerging origins of atherosclerotic etiology and explore intervention targets
  • identify causative risk factors and treat according to guidelines to reduce burden of CV disease
  • evaluate effectiveness and potential limitations of current and emerging pharmacotherapy options for LDL reduction
  • review the latest guidelines and surrogate marker targets for management of diabetic heart disease
  • discuss evidence from late-breaking trial results and the impact on cardiovascular care

Why attend this symposium?

This conference brings together the most exciting advances in cardiovascular disease and related cardiometabolic and cardiorenal medicine, from treatment to prevention, and innovation to application. The program is unique because of its translational theme. The global faculty and participating audience present the faces of cardiovascular medicine with a truly international perspective. As this is our 20th anniversary, we are very excited to welcome you to help us celebrate!

Who should attend?

Cardiologists, Internists & Primary Care Physicians; Cardiovascular Surgeons; Pediatric Cardiologist, Allied Health Professionals (ACNP, Nurses, Pharmacists); Heart Failure Care Teams; Trainees; Clinical Researchers; Research Scientists.



Shanas Mohamed, RN, BScN, CMP
Toronto General Hospital (UHN)
200 Elizabeth Street, 12 Eaton RM 325A,
Toronto, ON, M5G 2C4
Telephone +1 416-340-3721

Allison Conley
University of Ottawa Heart Institute
40 Ruskin Street,
Ottawa, ON, K1Y 4W7